MYR 0.61
(0.83%)
Year | EBITDA | EBITDA Growth |
---|---|---|
2023 | 28.58 Million MYR | -3.78% |
2022 | 32.55 Million MYR | 23.18% |
2021 | 26.42 Million MYR | 53.97% |
2020 | 17.16 Million MYR | 542.63% |
2019 | 17.88 Million MYR | 0.0% |
Year | EBITDA | EBITDA Growth |
---|---|---|
2024 Q1 | 7.75 Million MYR | -7.85% |
2024 Q2 | 10.09 Million MYR | 18.89% |
2023 Q3 | 7.46 Million MYR | -9.07% |
2023 FY | - MYR | -3.78% |
2023 Q2 | 8.2 Million MYR | 13.2% |
2023 Q1 | 7.24 Million MYR | -2.91% |
2023 Q4 | 8.41 Million MYR | 12.8% |
2022 Q3 | 8.34 Million MYR | 0.0% |
2022 FY | - MYR | 23.18% |
2022 Q4 | 7.46 Million MYR | -10.5% |
2021 FY | - MYR | 53.97% |
2020 FY | - MYR | 542.63% |
2019 FY | - MYR | 0.0% |
Name | EBITDA | EBITDA Difference |
---|---|---|
Artroniq Berhad | -695 Thousand MYR | 4212.95% |
QES Group Berhad | 33.26 Million MYR | 14.066% |
Pharmaniaga Berhad | 7.34 Million MYR | -289.017% |
Apex Healthcare Berhad | 441.93 Million MYR | 93.532% |